GRI Bio’s updated materials highlight GRI-0621’s 0% treatment-related cough rate in the Phase 2a idiopathic pulmonary fibrosis study. The presentation identifies an adaptive Phase 2b/3 as the next step, with the proposed design described as saving 12-24 months and ~$50M versus sequential studies, subject to FDA agreement.

Key Highlights

  • GRI-0621 recorded 17% diarrhea versus 33% for placebo in the IPF-02 study.
  • The presentation describes an adaptive Phase 2b/3 design as potentially saving 12-24 months and ~$50M against sequential studies.
  • GRI Bio said GRI-0621 showed no treatment-related discontinuations to date.

The update was issued on September 8, 2026. GRI (NASDAQ: GRI)-0621 is identified in the materials as oral tazarotene, with the program described as positive across Phase 2 endpoints.

GRI-0621 Data Update

The presentation identifies GRI-0621 as a selective RARβ/RARγ agonist being evaluated for idiopathic pulmonary fibrosis. Its biomarker framework spans transcriptomic, proteomic, cellular and clinical readouts, with the materials describing immune rebalancing, fibrolysis, lung repair, antitussive activity and gastrointestinal protection. The IPF-02 data show treatment-related cough at 0% for GRI-0621, compared with 25% for placebo. The presentation also reports no hepatic, blood-pressure or drug-drug interaction signal. The filing lists no treatment-related discontinuations to date and cites 1,700+ patients with prior safety history from topical tazarotene use in support of oral key development.

Proposed Key Study

GRI Bio (NASDAQ: GRI) describes a single adaptive Phase 2b/3 study as the planned next step for GRI-0621. The proposed design is described as replacing sequential Phase 2b and Phase 3 studies, with the presentation estimating savings of 12-24 months, approximately 150-200 subjects and ~$50M compared with sequential trials. The materials also state that the adaptive key study could deliver data 16-24 months faster than sequential Phase 2b and Phase 3 studies. The program has Orphan Drug designation, FDA fee waivers and priority-review Leverage listed among its regulatory features. Orphan drug designation is described as providing 7-year U.S. exclusivity from approval.

IPF Program Positioning

GRI Bio’s presentation places GRI-0621 within a potential $6-9B U.S. branded idiopathic pulmonary fibrosis opportunity by 2035. The filing identifies AFT market growth of 6-9% CAGR and says the U.S. represents 75% of branded revenue. The materials describe three new Patent families filed in 2026 covering a standard-of-care combination, antitussive activity and gastrointestinal protection. The baseline loss-of-exclusivity runway is described as extending into the late 2030s, with a potential extension into the late 2040s if the new patent families are granted. The presentation reports that GRI-0621 produced 150% more subjects with no decline in forced vital capacity than standard of care, alongside reduced dyspnea and reported basement-membrane and AT1/AT2 repair findings. It also identifies GRI-0803 and a library of 500+ proprietary compounds as other pipeline assets.